{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T07:02:15Z","timestamp":1747206135266,"version":"3.40.5"},"reference-count":0,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CMAR"],"DOI":"10.2147\/cmar.s215585","type":"journal-article","created":{"date-parts":[[2019,9,8]],"date-time":"2019-09-08T22:28:46Z","timestamp":1567981726000},"page":"8277-8284","source":"Crossref","is-referenced-by-count":0,"title":["<p>Gemcitabine, cisplatin, prednisone, and thalidomide for relapse and refractory peripheral T-cell lymphoma: a retrospective study from China<\/p>"],"prefix":"10.2147","volume":"Volume 11","author":[{"given":"Xiangli","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YuFeng","family":"Shang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xudong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2876-5182","authenticated-orcid":true,"given":"Zhaoming","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingzhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2019,9]]},"container-title":["Cancer Management and Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=52640","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=52640","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,8]],"date-time":"2019-09-08T22:28:47Z","timestamp":1567981727000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/gemcitabine-cisplatin-prednisone-and-thalidomide-for-relapse-and-refra-peer-reviewed-article-CMAR"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":0,"URL":"https:\/\/doi.org\/10.2147\/cmar.s215585","relation":{},"ISSN":["1179-1322"],"issn-type":[{"type":"electronic","value":"1179-1322"}],"subject":[],"published":{"date-parts":[[2019,9]]}}}